What is the STAR Offering mentioned in the filing?

The STAR Offering refers to an offering of BeOne Medicines Ltd.'s ordinary shares (RMB Shares) on the STAR Market in China. This filing details the agreements and terms related to this proposed offering, which aims to raise significant capital for the company.

How much money is BeOne Medicines Ltd. expected to raise from this offering?

The company expects to raise gross proceeds of approximately RMB 22.2 billion, which is equivalent to approximately US$3.5 billion, before deducting underwriting commissions and other offering expenses.

How will the funds raised from the STAR Offering be used?

The net proceeds from the STAR Offering are intended to fund the company's research and clinical development activities, the construction of research and development centers and a manufacturing plant in China, the expansion of its sales and marketing force in China, and for general corporate purposes and working capital.

What are the potential risks associated with this offering?

A key risk highlighted is the potential adverse impact of a triple listing (on NASDAQ, the Hong Kong Stock Exchange, and the STAR Market) on the liquidity and value of the company's various listed securities. The company also notes that the representations and warranties in the U.S. Letter Agreement should not be relied upon by investors as a characterization of the company's actual state of affairs.

ONC/BEIGF 8-K: Material Agreements

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on December 6, 2021, detailing significant progress on its proposed STAR Market offering (also referred to as the RMB Shares offering). The company entered into a PRC Underwriting Agreement to offer 115,055,260 ordinary shares (potentially up to 132,313,260 shares) at RMB 192.60 per share. This offering is expected to generate gross proceeds of approximately RMB 22.2 billion, or US$3.5 billion. The proceeds are earmarked for funding research and development, constructing facilities in China, expanding its sales and marketing teams, and for general corporate purposes.

Key Highlights

1BeOne Medicines Ltd. has finalized terms for a significant offering of ordinary shares on China's STAR Market.
2The offering is expected to raise approximately US$3.5 billion in gross proceeds.
3The company plans to issue 115,055,260 ordinary shares, with an option to issue up to 132,313,260 shares.
4The shares will be offered at RMB 192.60 per share.
5Proceeds will be used to advance R&D, build infrastructure in China, and expand commercial operations.
6A risk factor highlights the potential adverse impact of a triple listing (NASDAQ, HKEx, STAR Market) on the liquidity and value of the company's securities.
7The company has entered into both a U.S. Letter Agreement and a PRC Underwriting Agreement related to this offering.

BeOne Medicines Ltd. 8-K Report, Material Agreement (Dec 6, 2021)

Summary

Key Highlights

Frequently Asked Questions